HEALTHFOX NEWS
FDA delays cost Americans trillions and slow lifesaving drugs, new report says
A new report claims delaying Food and Drug Administration (FDA) reviews costs trillions in economic value and slows access to lifesaving drugs. The report estimates cutting FDA effectiveness-review timelines by one year could generate over $10 trillion in economic value by accelerating treatments and innovation. Proposed reforms include faster clinical trials, greater use of artificial intelligence, and expanded 'right to try' programs.
Mentioned
Related Signal
Adjacent reporting
- FDA delays cost Americans trillions and slow lifesaving drugs, new report says
- Trump's drugmaker deals may save economy $529B over 10 years, White House says
- STAT+: Pharmalittle: We’re reading about U.S. pressuring Germany on drug prices, FDA upheaval and biotech clinical trials, and more
- From decades to years - AI could speed search for brain drugs hiding in plain sight
- STAT+: FDA to reconsider treatment for rare cancer after surprise rejection
- STAT+: Medicare is spending far less than expected on new Alzheimer’s drugs